Why It Matters

Abbott Laboratories has added PhronesisDC LLC to its already extensive roster of outside lobbying firms, registering the new relationship in April 2026. The Abbott Laboratories lobbying disclosure covers four issue areas: health care, taxation, retirement, and torts. Retirement and torts are new additions to the company's lobbying portfolio.

Abbott has maintained a broad and well-funded legislative advocacy operation for years, working with more than a dozen outside firms alongside a large in-house team. Adding PhronesisDC signals the company is deepening its presence on tax and retirement policy at a moment when Congress is actively reshaping both.

The firm's existing client list, which includes Koch Government Affairs LLC, Amazon.com Inc., and Business Roundtable Inc., suggests PhronesisDC has particular depth on tax issues. That aligns with Abbott's ongoing engagement on OECD global minimum tax negotiations and domestic corporate tax reform.

By the Numbers

Abbott Laboratories' lobbying activity in 2025 reflects a company with one of the more substantial lobbying operations in the health care sector.

The PhronesisDC registration lists no filing amount, consistent with a new client registration. Three lobbyists are named on the account: Jack Wilkinson, Brett Quick, and Brendan Dunn. Quick brings experience from the House Financial Services Committee and the Senate Banking Committee's National Security and International Trade and Finance Subcommittee. Dunn served as counsel to the Senate Judiciary Committee and as special counsel to the Senate Finance Committee. Wilkinson worked briefly in the office of Rep. Alexander X. Mooney (R-WV).

Abbott's in-house lobbying team includes roughly ten registered lobbyists, several of whom have committee backgrounds in health policy, appropriations, and tax. External firms on Abbott's broader roster include Akin Gump Strauss Hauer & Feld LLP, Kountoupes Denham Carr & Reid LLC, S-3 Group LLC, and McDermottPlus LLC, among others.

The Agenda

The PhronesisDC registration covers four broad issue codes with no specific legislation or issue text disclosed, which is standard for new client registrations filed before substantive lobbying work begins.

The four areas are:

  • Health Issues (HCR)
  • Taxation/Internal Revenue Code (TAX)
  • Retirement (RET)
  • Torts (TOR)

Retirement and torts are new additions to Abbott's lobbying disclosures. In prior filings, the company lobbied on health care, agriculture, trade, Medicare and Medicaid, budget and appropriations, and food safety. The expansion into retirement and torts through PhronesisDC suggests Abbott may be engaging on employee benefits policy and litigation reform, though the disclosure does not specify.

Broader Context

Several policy developments are running parallel to Abbott's expanded lobbying registration.

On taxation, a January 2026 agreement among more than 145 countries updated the OECD global minimum tax framework in ways that partially shield U.S.-headquartered multinationals. Reuters reported that Treasury Secretary Bessent called the deal "a historic victory in preserving U.S. sovereignty." However, the Conference Board noted that U.S. companies will still face qualified domestic minimum top-up taxes in 2026 and beyond, keeping the issue alive for corporate tax lobbying.

On health care, Abbott's FreeStyle Libre continuous glucose monitor faces a shifting Medicare reimbursement environment. The HHS Office of Inspector General found that Medicare payments for CGMs exceeded supplier costs and retail prices, and recommended payment reductions. CMS issued a proposed rule in July 2025 to pursue those reductions.

On trade, Medilink UK reported that a 10% U.S. tariff on UK medical device exports adds approximately £12 million annually in supply chain costs. Supply Chain Dive noted that tariffs pressured medtech gross margins in 2025 and are expected to continue doing so in 2026.

Between the Lines

Congressional activity on Abbott's core issue areas has been active in recent months. An April 2026 House subcommittee hearing examined the policies and priorities of the Employee Benefits Security Administration, touching on ERISA protections for retirement and health plans, areas directly relevant to Abbott's new lobbying focus.

On health care, multiple hearings have addressed pharmaceutical pricing and pharmacy benefit manager practices. The Senate Health, Education, Labor, and Pensions Committee held a hearing on making medicines more affordable through competition in April 2026. Relevant legislation includes the RESULTS Act, which would reform how Medicare pays for clinical laboratory tests, and the Genomic Answers for Children's Health Act, which would require Medicaid coverage of whole genome sequencing for children with suspected genetic disorders.

Competitive Landscape

PhronesisDC's existing lobbying registration filings show the firm already represents clients with overlapping interests on tax policy. Koch Government Affairs LLC, PhronesisDC's highest-paying client at $370,000 over the past year, has lobbied on tax and retirement policy. American Council of Life Insurers, BlackRock Funds Services Group LLC, and Business Roundtable are also PhronesisDC clients with active tax and retirement lobbying. Abbott will be operating alongside those clients as Congress continues work on tax legislation.

The Bottom Line

Abbott's addition of PhronesisDC reflects a targeted expansion into tax and retirement policy, two areas where Congress is moving legislation and where Abbott has growing interests. The company's overall lobbying infrastructure remains substantial, and the new registration adds lobbyists with relevant committee backgrounds in tax and financial services. The specific issues Abbott plans to pursue through PhronesisDC will become clearer when quarterly reports are filed later this year.

Access the Legis1 platform for comprehensive political news, data, and insights.